Drug safety evaluation of exemestane. - Wikidata - wikimedia - TriplyDB

Drug safety evaluation of exemestane.

Drug safety evaluation of exemestane.

http://www.wikidata.org/entity/Q37856307

about

Computational repositioning and preclinical validation of pentamidine for renal cell cancer.Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).

P2860

Q33875574-D9147DC1-27F1-480E-98A7-6A38AB3B5525 Q37585180-BDB2DB20-ABC5-416B-ACCE-CDEFEB09F6EF

P2860

Drug safety evaluation of exemestane.

http://www.wikidata.org/entity/Q37856307

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Drug safety evaluation of exemestane.

@en

Drug safety evaluation of exemestane.

@nl

type

label

Drug safety evaluation of exemestane.

@en

Drug safety evaluation of exemestane.

@nl

prefLabel

Drug safety evaluation of exemestane.

@en

Drug safety evaluation of exemestane.

@nl

P1433

Q37856307-C359403F-F15D-41B4-9277-53155EB3B887

P1476

Q37856307-0A9E56FD-3FE5-4109-9A4B-7B4D3C24D7DB

P2093

Q37856307-D7D7B9FC-8618-4367-80B5-1011A948D791

Q37856307-DAF14F74-E769-4FBA-B0C0-E900F27E862A

Q37856307-EAA35F9C-791F-4814-81DE-B9EDBF878110

P2860

Q37856307-032487AE-F039-4AA0-AC6D-6905B417CA0B

Q37856307-04B8D5CB-6E8B-4F2D-BE49-2791564B6FBE

Q37856307-054D6A0F-B3DB-403D-B640-51E40A67B1FD

Q37856307-067DBD73-9A27-4196-B173-4079C5A28F37

Q37856307-0821F355-73B1-4A82-BE6F-37928E46E060

Q37856307-0B4388DB-4DDF-4748-9D0D-2C56F741E612

Q37856307-100F81BE-E61C-4857-9D21-8ACBC3DB49C2

Q37856307-11B307D8-1899-4261-8825-BFE82A0942CB

Q37856307-19C6D576-82EF-465D-A434-85B432A4A4A5

Q37856307-1D3B33C6-9D1F-4630-80FD-65A6F1FDE0F2

P304

Q37856307-B77DC880-A172-4A2C-9529-26AE372A2691

P31

Q37856307-A31C6A68-CE13-432C-B11A-DCE28ADF1A50

P356

Q37856307-9A30C7DA-C94E-481A-96F0-37B850757D6B

P407

Q37856307-52A62F03-F014-4922-942D-41075DAA1253

P433

Q37856307-2CED110D-5B72-4873-B94F-D6ADA11DB3CF

P478

Q37856307-D731D15F-1AD6-453C-9B07-56C113348AFC

P577

Q37856307-E820FCE7-AEB3-4BE8-A510-9C8B7F0DCEBA

P698

Q37856307-14768948-7A0C-4366-B2B9-077CC7FB8AE4

P356

14740338.2011.567264

P1433

Expert Opinion on Drug Safety

P1476

Drug safety evaluation of exemestane.

@en

P2093

Anneleen Lintermans

http://www.w3.org/2001/XMLSchema#string

Patrick Neven

http://www.w3.org/2001/XMLSchema#string

Robert Paridaens

http://www.w3.org/2001/XMLSchema#string

P2860

Letrozole sensitizes breast cancer cells to ionizing radiation

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility

Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis.

A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.

Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.

Aromatase and leiomyoma of the uterus.

P304

473-487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2011.567264

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21428848

http://www.w3.org/2001/XMLSchema#string